Contract award · 16 Dec 2020

Contract for supply of herpes zoster (shingles) vaccine(recombinant, adjuvanted)

Department of Health and Social Care awarded “Contract for supply of herpes zoster (shingles) vaccine(recombinant, adjuvanted)” to GlaxoSmithKline UK Limited for £66.1m on 16 Dec 2020. Awarded without open competition.

No competitionMedical equipment & pharmaceuticals London

BuyerDepartment of Health and Social Care

Value £66.1m

WinnerGlaxoSmithKline UK Limited

Awarded without open competition

Awarded without open competition. The buyer went directly to one or a few suppliers instead of advertising the contract. Procurement rules allow this only in specific cases, such as extreme urgency, when only one supplier can do the work, or for call-offs from an existing framework.

What “without competition” means

Buyer: Department of Health and Social Care · Ministry or any other national or federal authority, including their regional or local subdivisions
Supplier: GlaxoSmithKline UK Limited
Value: £66,131,483
Procedure: Award procedure without prior publication of a call for competition
Sector: Medical equipment & pharmaceuticals · Vaccines (CPV 33651600)
Region: London
Official notice: 000854-2021 on Find a Tender
Timeline: Contract date16 Dec 2020

Published15 Jan 2021Published 30 days after the contract date

Description

The provision of herpes zoster (shingles) vaccine(recombinant, adjuvanted) deliveries will be required from 1 April 2021 to 31 March 2023, with an option to extend for up to an additional 24 months.